Do zapamiętania

• U małego dziecka, które łatwo się siniaczy, powinno się wykonać podstawowe badania krzepnięcia krwi.

• Jedynym sposobem uniknięcia artropatii hemofilowej jest rozpoczęcie stałej profilaktyki krwawień przed pojawieniem się zmian w stawach u dziecka z ciężką postacią hemofilii.

• W razie wystąpienia krwawienia u dziecka z hemofilią konieczne jest jak najszybsze wstrzyknięcie odpowiedniego koncentratu czynnika krzepnięcia.

• Inhibitory czynnika VIII lub IX pojawiają się w następstwie leczenia chorego na hemofilię koncentratami odpowiedniego czynnika krzepnięcia.

• Każdy chory na hemofilię powinien mieć przy sobie dokument z podstawowymi danymi na temat choroby.

• Wywołanie tolerancji immunologicznej jest jedynym sposobem eliminacji inhibitora czynnika VIII lub IX u chorego na hemofilię.

• Standardem leczenia ciężkiej postaci hemofilii jest leczenie domowe.

• Celem leczenia dziecka chorego na hemofilię jest zapewnienie prawidłowego rozwoju przez umożliwienie pełnego uczestniczenia w życiu rodziny i grupy rówieśniczej.

Piśmiennictwo

1. Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia. 1995;1(suppl.1):8-13.

2. Franchini M, Lippi G. Recombinant factor VIII concentrates. Semin Thromb Hemost. 2010;36(5):493-497.

3. Mannucci PM. Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B. Haemophilia. 1995;1(suppl.1):14-20.

4. Mannucci PM, Ghirardini A. Desmopressin twenty years after. Thromb Haemost. 1997;78:958.

5. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med. 1997;241:395-400.

6. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med. 2007;357(6):535-544.

7. Ljung R, Aronis-Vournas S, Kurnik-Auberger K, et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia. 2000;6:619-624.

8. Richards M, Wiliams M, Chalmers E, et al. A United Kingdom Haemophilia Centre Doctors’ organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. British Journal of Haematology. 2010;149: 498-507.

9. Kurnik K, Bildlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immmunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2009:1-7. DOI:10.1111/j.1365-2516.2009.02122.x

10. Lambert T, Recht M, Valentino A, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007;13:233-243.

11. Windyga J, Łopaciuk S, Stefańska E. Haemophilia in Poland. Haemophilia. 2006;12:52-57.

12. Tencer T, Roberson C, Duncan K, Johnson K, Shapiro A. A haemophilia treatment centre-administered disease management programme in patients with bleeding disorders. Haemophilia. 2007;13:480-488.

13. Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia. 2006;12:579-590.

14. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA Novoseven Comparative (FENOC) study. Blood. 2007;109:546-551.

15. Rangarajan S, Yee TT, Wilde J. Experience of four UK comprehensive care centres using FEIBA ® for surgeries in patients with inhibitors. Haemophilia. 2010:1-7. DOI: 10.1111/j.1365-2516.2010.02360.x

16. Lauroua P, Ferrer A-M, Guérin V. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. Haemophilia. 2009;15:1300-1307.

17. Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost. 2006;4:367-371.

18. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia. 2008;14: 898-902.

19. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 µg kg-1-dose rFVIIa vs. Standard 90 µg kg-1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: randomized comparision. Haemophilia. 2008;14:287-294.

20. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years of the „Bonn protocol“. Vox Sang. 1996; 70 (suppl.1):30-35.

21. Wight J, Paisley S, Knight C. Immune tolerance in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9:36-46.

22. Astermark J, Morado M, Rocino A, et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia. 2006;12(4):363-371.

23. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335-1344.

24. Belvini D, Salviato R, Radossi P, Pierobon F, Mori P, Castaldo G, Tagariello G. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica. 2005;90:635-642.

25. Warrier I. Management of haemophilia B patient with inhibitors and anaphylaxis. Haemophilia. 1998;4:574-576.

26. Ewenstein BM, Takemodo C, Warrier I, Lusher J, Saidi P, Eisele J, et al. Nephrotic syndrome as a complication of immune tolerance in haemophilia B. Blood. 1997;89:1115-1116.

27. Di Michele DM, Hoots WK, Pipe W, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13(suppl.1):1-22.

Do góry